Showing 31 results
- https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iv-study-showing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-preventionThe first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and…
- https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-preventionMigraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-…
- https://www.novartis.com/news/media-releases/new-data-aan-reinforce-novartis-commitment-transforming-lives-people-all-ages-who-live-neurological-conditionsNovartis leads the way at AAN with 52 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple…
- https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-evidence-aan-reinforcing-robust-and-consistent-efficacy-aimovigtm-erenumab-migraine-patients-multiple-treatment-failuresThe LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials …
- https://www.novartis.com/news/media-releases/novartis-delivers-solid-growth-second-quarter-and-continues-transformation-focused-medicines-companyNet sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…
- https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-ein-solides-wachstum-und-setzt-die-transformation-zu-einem-fokussierten-arzneimittelunternehmen-fortDer Nettoumsatz steigt um 5% (kWk[1], +7% USD), vor allem dank folgender Beiträge: Cosentyx erreicht USD 701 Millionen (+40% kWk) mit starken Zuwächsen bei allen Indikationen in den USA und der…
- https://www.novartis.com/news/media-releases/novartis-realise-une-solide-croissance-au-deuxieme-trimestre-et-poursuit-sa-transformation-en-une-entreprise-axee-sur-les-medicamentsHausse du chiffre d'affaires net de 5% (tcc[1], +7% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 701 millions, (+40% tcc), enregistrant une forte croissance dans toutes ses…
- https://www.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-core-margin-expansion-built-leading-advanced-therapy-platforms-and-focused-company-2018Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0…
- https://www.novartis.com/news/media-releases/novartis-updates-migraine-collaboration-amgenBasel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of…
- https://www.novartis.com/news/media-releases/novartis-erzielt-2018-ein-kraftiges-umsatzwachstum-bei-gleichzeitiger-steigerung-der-kerngewinnmarge-baut-wegweisende-therapieplattformen-auf-und-fokussiert-das-unternehmenDer Nettoumsatz steigt im Geschäftsjahr um 5% (kWk[1], +6% USD) dank starker Performance der Wachstumstreiber: Die Geschäftseinheit Pharmaceuticals wächst um 7% (kWk), getragen von Cosentyx mit…